Analysis of BRAF mutation status in high-risk malignant melanoma patients having received HD IFNa therapy in adjuvant setting.
Zuzana Hlavata
No relevant relationships to disclose
Tomas Salek
No relevant relationships to disclose
Iveta Andrezalova
No relevant relationships to disclose
Jozef Dolinsky
No relevant relationships to disclose
Veronika Svabova
No relevant relationships to disclose
Stefan Porsok
No relevant relationships to disclose
Jitka Berkovcova
No relevant relationships to disclose
Iveta Waczulikova
No relevant relationships to disclose